Seedlabs

Waist-First 20-Week Check for Semaglutide Heart Patients

A clinic kit that uses waist measurements instead of weight to track how well heart patients are responding to medication.

A ready-to-use clinic kit for the standard 20-week check-in of heart-disease patients taking semaglutide that leads with a tape measure instead of a scale, because the trial shows waist shrinkage — not pounds lost — tracks the drug's heart protection.

MedicineDiabetes Treatment and Management
Metabolism and Genetic DisordersCardiology clinic GLP-1 therapy follow-up and patient persistence

Concept

A point-of-care "week-20 review" kit for patients with overweight/obesity and established cardiovascular disease (without diabetes) on once-weekly semaglutide 2.4 mg. It standardizes one change to the routine GLP-1 follow-up visit: waist circumference, measured with a protocolized tape method, becomes the headline number, and weight becomes secondary. A one-page decision aid has three branches: (1) waist down — show the patient the centimeters lost and explain this tracks the visceral-fat component of the drug's heart protection; (2) weight stalled but waist down — explicitly frame the visit as a cardiac win, since the trial found no link between week-20 weight loss and later cardiovascular events; (3) both stalled — the aid states in plain language that heart protection was consistent regardless of body size or weight change, so a "non-responder on the scale" is not a non-responder for the heart. Delivered as a clinic workflow card plus patient handout, or embedded as a milestone in existing digital cardiometabolic coaching programs.

Why now

The prespecified SELECT analysis (17,604 patients, 41 countries, 804 sites) supplies the numbers: on semaglutide, week-20 weight change showed no linear association with subsequent MACE risk, while greater week-20 waist reduction was associated with lower subsequent MACE risk, and week-104 waist reduction with lower in-trial MACE. An estimated 33% of the drug's MACE benefit was mediated through waist circumference reduction (HR 0.86, 95% CI 0.77–0.97 after adjustment for time-varying waist change). Benefits were consistent across all baseline weight and waist categories, and each 5 cm smaller baseline waist predicted ~4% lower MACE risk (HR 0.96). Today's follow-up visits anchor on the scale — the one metric the trial found uninformative for cardiac prognosis on treatment — while a tape measure captures the mediated component of benefit and gives stalled-scale patients a concrete reason to persist.

Written by GLM · 10 Oct 2026

AI assessment

Backed by 1 paper92

A highly focused, evidence-backed clinical tool that pivots the GLP-1 success metric from weight to waist circumference to improve patient persistence and cardiac prognosis tracking.

Evidence strength
5/5
The idea is directly derived from a prespecified analysis of the massive SELECT trial (17,604 patients), specifically utilizing the finding that waist reduction—not weight loss—correlates with MACE risk reduction.
Market pull
4/5
Cardiology clinics and digital health providers (like Omada or Noom) have a strong incentive to increase patient persistence and provide evidence-based 'wins' to patients who plateau on the scale.
Novelty & moat
4/5
While other catalog ideas focus on registries or cessation, this is the first to propose a specific, evidence-driven change to the point-of-care clinical encounter for active patients.
Feasibility
5/5
The MVP is essentially a protocolized measurement guide and a decision-aid handout, requiring almost zero technical development to deploy.
Wedge clarity
5/5
The 'Week-20 Check' is a sharp, time-bound entry point that targets a specific clinical milestone in the patient journey.
Simplicity / focus
5/5
It avoids 'platform' creep, focusing entirely on one specific measurement shift and its corresponding patient communication.

Scored by Gemma 4 · 10 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Novo Nordiskcompany

    Maker of Wegovy (semaglutide 2.4 mg) and sponsor of SELECT; a standardized week-20 waist-first review gives prescribers an evidence-based reason to keep CVD patients on therapy when the scale stalls, directly supporting persistence in the CV-indication population.

  • Omada Healthcompany

    Runs digital cardiometabolic and GLP-1 support programs; a week-20 waist milestone gives its health coaches a concrete, trial-backed non-scale metric to keep members engaged after weight plateaus.

  • Cleveland Clinicorganization

    Its Heart, Vascular & Thoracic Institute treats large numbers of obesity-CVD patients on semaglutide; the kit standardizes the 20-week check across hundreds of cardiologists and APPs with a single protocol.

  • American Heart Associationorganization

    Publishes patient education on obesity and heart disease; a plain-language waist-first progress message fits its science advisories and patient toolkits on obesity management in CVD.

  • Noomcompany

    Its Noom Med offering supports patients on GLP-1s; a non-scale, waist-based progress frame helps members whose weight loss plateaus stay in the program rather than churning.

Research it builds on

  1. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial
    John Eric Deanfield, Abraham Michael Lincoff, Steven E. Kahn et al. · 2025 · 136 citations
    All ideas from this paper →
Leave feedback
feasibility